Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.47 |
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
| ▸ | FNTB | P49356 | 2/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16711054 | 1.00 | GLP1R (0.54) | GLP1RFOLH1NOD1FNTAFNTB | |
| SCHEMBL16947841 | 0.95 | GLP1R (0.53) | GLP1RFOLH1NOD1FNTAFNTB | |
| SCHEMBL16638265 | 0.95 | GLP1R (0.53) | GLP1RFOLH1NOD1FNTAFNTB | |
| SCHEMBL16638269 | 0.95 | GLP1R (0.53) | GLP1RFOLH1NOD1FNTAFNTB | |
| SCHEMBL16711021 | 0.95 | GLP1R (0.53) | GLP1RFOLH1NOD1FNTAFNTB | |
| SCHEMBL16638314 | 0.95 | GLP1R (0.53) | GLP1RFOLH1NOD1FNTAFNTB | |
| SCHEMBL16947838 | 0.95 | GLP1R (0.53) | GLP1RFOLH1NOD1FNTAFNTB | |
| SCHEMBL16947837 | 0.95 | GLP1R (0.53) | GLP1RFOLH1NOD1FNTAFNTB | |
| SCHEMBL16638264 | 0.95 | GLP1R (0.53) | GLP1RFOLH1NOD1FNTAFNTB | |
| SCHEMBL16638263 | 0.95 | GLP1R (0.53) | GLP1RFOLH1NOD1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133374-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133374-A1 | Double-Acylated GLP-1 Derivatives | GLP1R, GIPR, GPR119 | GLP1R 1/4885FOLH1 1143/4885NOD1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.